ETHC.com Patient Resources ETHC Physicians ETHC Locations Research


About Us
Contact Us
ETHC News & Events
ETHC Careers
I-40 2008 Map
Site Map
 

Clinical Research

Current Clinical Trials at East Tennessee Heart Consultants

  • ACTIVE - Atrial Fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events
     
  • ASPIRE - A 36-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of aliskiren on the prevention of left ventricular remodeling in high risk post-acute myocardial infarction patients when added to optimized standard therapy.
     
  • ATHENA - A Placebo-Controlled, Double-Blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 400mg bid for the Prevention of Cardiovascular Hospitalization or Death From Any Cause in Patients with Atrial Fibrillation/Atrial Flutter (AF/AFL)
     
  • AVANT GARDE - A randomized, double-blind, parallel-group, placebo-controlled, multinational clinical trial to evaluate the efficacy of aliskiren and valsartan versus placebo in lowering levels on NT-proBNP in stabilized patients post acute coronary syndromes
     
  • EARLY ACS - Early Glycoprotein IIb/IIIa Inhibition on Non-ST-segment Elevation Acute Coronary Syndrome: A Randomized, Placebo-Controlled Trial Evaluating the Clinical Benefits of Early Front-loaded Eptifibatide in the Treatment of Patients with Non-ST-segment Elevation Acute Coronary Syndrome
     
  • OAT - Occluded Artery Trial
     
  • PEGASUS CRT Study - Pacing Evaluation - Atrial Support Study in Cardiac Resynchronization Therapy
     
  • RELAX (REvascularization of Leg Arteries with the Xpert™ stent)
     
  • ROCKET AFIB - A Prospective, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once Daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-Dose Oral Warfarin for the Prevention of Strokes and Non-Central Nervous System Systemic Embolism in Subjects with Non-Valvular Atrial Fibrillation Protocol 39039039AFL3001; Phase 3, (EudraCT number 2006-004595-13), BAY59-7939/11630, JNJ39039039 (rivaroxban, BAY 59-7939)
     

 

This page has been viewed 241 time(s) since May 29, 2007.